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Abstract 
High tumor recurrence is frequently observed in patients with urinary bladder cancers (UBCs), with the need 
for biomarkers of prognosis and drug response. Chemoresistance and subsequent recurrence of cancers are 
driven by a subpopulation of tumor initiating cells, namely cancer stem-like cells (CSCs). However, the 
underlying molecular mechanism in chemotherapy-induced CSCs enrichment remains largely unclear. In this 
study, we found that during gemcitabine treatment lncRNA-Low Expression in Tumor (lncRNA-LET) was 
downregulated in chemoresistant UBC, accompanied with the enrichment of CSC population. Knockdown of 
lncRNA-LET increased UBC cell stemness, whereas forced expression of lncRNA-LET delayed 
gemcitabine-induced tumor recurrence. Furthermore, lncRNA-LET was directly repressed by gemcitabine 
treatment-induced overactivation of TGFβ/SMAD signaling through SMAD binding element (SBE) in the 
lncRNA-LET promoter. Consequently, reduced lncRNA-LET increased the NF90 protein stability, which in 
turn repressed biogenesis of miR-145 and subsequently resulted in accumulation of CSCs evidenced by the 
elevated levels of stemness markers HMGA2 and KLF4. Treatment of gemcitabine resistant xenografts with 
LY2157299, a clinically relevant specific inhibitor of TGFβRI, sensitized them to gemcitabine and significantly 
reduced tumorigenecity in vivo. Notably, overexpression of TGFβ1, combined with decreased levels of 
lncRNA-LET and miR-145 predicted poor prognosis in UBC patients. Collectively, we proved that the 
dysregulated lncRNA-LET/NF90/miR-145 axis by gemcitabine-induced TGFβ1 promotes UBC 
chemoresistance through enhancing cancer cell stemness. The combined changes in 
TGFβ1/lncRNA-LET/miR-145 provide novel molecular prognostic markers in UBC outcome. Therefore, 
targeting this axis could be a promising therapeutic approach in treating UBC patients. 
Key words: tumor recurrence, cancer stem-like cells, lncRNA-LET, miRNA biogenesis, bladder cancer. 
Introduction 
Urinary bladder cancer (UBC) is highly 
recurrent. Although cytotoxic chemotherapeutic 
reagents such as gemcitabine (GEM) work well for 
most patients initially, a majority of patients treated 
with GEM progressively become unresponsive after 
multiple rounds of treatments, and ultimately lead to 
tumor relapse. Chemotherapies are usually 
administered in cycles for fractionated killing of 
unsynchronized proliferating cancer cells; meanwhile 
they allow recovery of cells in normal tissues. 
However, this regimen also provides an opportunity 
for residual cancer cells to survive (1). Results from 
recent studies suggest that a small subpopulation of 
cells with cancer stem-like properties has a survival 
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advantage in response to chemotherapy and may be 
responsible for tumor recurrence (2-5). This 
subpopulation is also known as cancer stem-like cells 
(CSCs) or tumor-initiating cells (TICs) because they 
retain the capacity of self-renewal and repopulation of 
the whole tumor bulk (6-8). However, the molecular 
mechanism in GEM-induced CSCs enrichment in 
UBC remains unclear, which hampers the application 
of treatments specifically targeting CSCs. 
Treatment-induced cancer cell death may also be 
accompanied with inflammation, which has been 
implicated in the development of chemoresistance 
(9-12). Some pro-inflammatory cytokines derived 
from either dying cancer cells or tumor 
microenvironment are involved in cancer relapse. 
TGFβ1 is one of the most potent cytokines capable of 
inducing epithelial-to-mesenchymal transition (EMT), 
which is highly associated with the characteristics of 
CSCs (13).  
Long noncoding RNAs (lncRNAs) are those 
RNA molecules with more than 200 nucleotides. 
Although lncRNAs do not code for any proteins, they 
have been implicated in different processes of cancer 
development including initiation, promotion and 
metastasis (14). Results from more recently reported 
studies also suggest that lncRNAs play important 
roles in the maintenance of cancer cell stemness and 
chemoresistance (15). Some lncRNAs appear to have 
the potential to be developed into prognosis 
biomarkers for chemotherapy (16). LncRNAs regulate 
gene expression at multiple levels, including 
transcriptional regulation through interacting with 
chromatin-modifying factors and post-transcriptional 
regulation through targeting mRNAs, miRNAs and 
proteins. How lncRNAs-mediated pro-inflammatory 
cytokines function in CSC and the downstream 
networks involved in chemoresistance are elusive. In 
this study, we found that CSCs were highly enriched 
in UBC in response to GEM treatment. 
Mechanistically, GEM treatment-mediated 
upregulation of TGFβ1 directly involved in the 
dysregulation of lncRNA-LET/NF90/miR-145 axis. 
Therefore, targeting this axis could be a potential 
therapeutic strategy with less recurrence. 
Materials and Methods 
Cell lines and human cancer tissues 
Human UBC cell lines, T24, 5637, J82, SW780, 
BIU87, ScaBER and UMUC3 were obtained from Cell 
Bank of Type Culture Collection, Chinese Academy of 
Science (Shanghai, China). Cells were maintained in 
RPMI1640 supplemented with 10% FBS, 100 units/ml 
penicillin and 100 μg/ml streptomycin at 37oC. J82 
cells were treated with 50 μg/ml cycloheximide 
(CHX; Sigma) or 20 μM MG-132 (Sigma) for 3, 6 or 12 
h before lysed for protein analysis. For TGFβ1 
experiment, UBC cells were treated with 2 nM TGFβ1 
(Proteintech, 100-21, Rocky Hill, NJ) for 48 h, and if 
needed, 10 nM SB431542 (Selleck Chemical, S1067, 
Boston, MA) was added 1 h prior to TGFβ1 treatment.  
UBC tissues (n = 60) and adjacent non-tumor 
tissues (n = 48) were collected from Nanjing Drum 
Tower Hospital affiliated to Nanjing University 
(Jiangsu, China) from January 2012 to October 2013. 
Fresh tissue samples were collected and processed 
within 10 min. Each sample was snap-frozen in liquid 
nitrogen and then stored at -80°C. The paired adjacent 
normal tissues were isolated from at least 3 cm away 
from tumor boarder and with no microscopic tumor 
cells. All cases were in accord with the following 
criteria: diagnosed by postoperative histopathology; 
complete follow-up data available; no metastasis 
before surgery; no other malignant disease; and no 
preoperative anticancer therapy. We defined tumor 
recurrence as any radiological or pathological tumor 
found after surgery. Tumor staging was defined 
according to the 7th Edition of 
Tumor-Node-Metastasis (TNM). The data do not 
contain any information that could identify the 
patients. Informed consent was obtained in 
accordance with the Declaration of Helsinki and the 
protocols were approved by the Nanjing Drum Tower 
Hospital Ethics Committee of Medicine for tissue 
sample collection (201203601).  
RNA isolation, quantitative reverse 
transcription-PCR (qRT-PCR), microarray and 
RNA immunoprecipitation (RIP) assays 
Total RNAs were extracted using TRIzol 
(Invitrogen, 15596018), following the manufacturer’s 
instructions. Small RNAs were extracted from tissue 
or cells using miRNeasy Mini isolation kit (QIAGEN). 
Reverse transcription of mRNA and miRNA was 
conducted using random primers and primers of 
stem-loop in TaKaRa system (Dalian, China), 
respectively. The levels of pri-miRNAs were 
quantified using the TaqMan Pri-miRNA assay kit 
(Assay ID Hs03303166_pri for pri-miR-143, Assay ID 
Hs03303169_pri for pri-miR-145; Applied 
Biosystems). Real-time PCR was performed using 
TaqMan Universal Master Mix II kit (Applied 
Biosystem). The levels of target genes were calculated 
based on the cycle threshold (Ct) values compared to 
a reference gene using formula 2-∆∆Ct. β-actin (ACTB) 
mRNA and U6 (RNU6B) snRNA were used as 
references for mRNA and mature miRNA, 
respectively. Sequences of the primer were listed in 
Table S1. For lncRNA profiling, Human lncRNA 
Discover PCR array (Bio-Serve Company, 
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BS-lncRNA002, Shanghai, China) was used. 
Affymetrix miRNA 4.0 microarray was used and 
performed by GMINIX Company (China).  
For RIP assays, cells were irradiated with 254 nm 
UV light (400 mJ/cm2), and homogenized in lysis 
buffer [150 mM KCl, 50 mM HEPES (pH 7.4), 2 mM 
EDTA, 0.5 mM DTT, 0.5% NP-40 containing 10 U/ml 
RNase inhibitor (TaKaRa) and a protease inhibitor 
cocktail (Roche)]. Cell extracts were incubated with 
anti-NF90 or IgG-coupled protein A beads for 4–6 h at 
4°C in NT2 buffer (50 mM Tris-HCl [pH 7.4], 150 mM 
NaCl, 1 mM MgCl2, 0.05% NP-40). After stringently 
washing the beads with washing buffer [50 mM 
HEPES (pH 7.4), 300 mM KCl, 0.5 mM DTT, 0.05% 
NP-40, protease inhibitor cocktail, and RNase 
inhibitor], total RNAs were extracted with TRIzol and 
subjected to RT-PCR assays. 
Immunoblotting 
Cells or tissues were lysed in RIPA buffer 
containing phosphatase inhibitor cocktail I (Sigma) 
and protease inhibitor cocktail mini-tablet (Roche 
Diagnostics, Indianapolis, IN). Proteins in the lysates 
were separated on SDS-PAGE and transferred onto 
polyvinylidenedifluoride membrane. After blocking 
with 5% non-fat milk in PBST, primary antibodies for 
ALDH1A1 (1:500, Proteintech Group, 22109-1-AP, 
Chicago, IL), CD44 (1:500, Cell Signaling Technology, 
#3570, Beverly, MA), KLF4 (1:500, Proteintech, 
11880-1-AP), HMGA2 (1:500, Proteintech, 
20795-1-AP), NF90 (1:1,000, ImmunoWay, YT5036, 
Newark, DE), FLAG-tag (1:2,000, Cell Signaling 
Technology, #2368), SMAD4 (1:500, Proteintech, 
10231-1-AP), p-SMAD2 (1:250, Phospho-Ser467, 
Signalway Antibody, 11322, College Park, MA), 
SMAD2 (1:500, AP0444) and β-actin (1:2,000, 
Bioworld) were used. The membranes were washed 
with PBST three times and incubated with 
horseradish peroxidase (HRP)-conjugated secondary 
antibody. The bands were visualized using enhanced 
chemiluminescence reagents (Millipore, WBKLS0100). 
Western blots were semi-quantified by Image J 
software (NIH). 
Sphere formation assay 
T24, 5637 cells and xenografts were trypsinized 
by TrypLE (Life Technologies) and washed in PBS. 
About 1.0×104 cells per well were seeded in the 6-well 
ultra-low attachment plates (Corning, Steuben 
County, NY) in DMEM/F12 culture medium 
supplemented with 10 ng/ml human recombinant 
bFGF and 10 ng/ml EGF (PeproTech, Rocky Hill, NJ). 
After culturing for 9-12 days with or without TGFβ1 
and/or SB-431542, spheres were photographed and 
spheres with the diameter greater than 50 µm were 
counted.  
Flow cytometry 
Cells with high ALDH enzyme activity was 
identified by ALDEFLUOER kit (Stem Cell 
Technologies, Vancouver, Canada). 5 µl of activated 
ALDEFLUOER reagent was added to 1 ml single cell 
suspension and incubated at 37°C for 40 min. An 
ALDH-specific inhibitor, Diethylaminobenzaldehyde 
(DEAB), was added prior to staining as a negative 
control.  
Luciferase assay 
Luciferase assays were performed using a 
luciferase assay kit (Promega). For TGFβ/SMAD 
pathway, T24 cells were transfected with plasmids 
containing wild-type or ∆SBE pGL3-LET-promoter 
and treated with vehicle control or TGFβ1, 
respectively. Cells were harvested and lyzed for 
luciferase assay 48 h post transfection. Renilla 
luciferase was used for normalization. 
In vivo tumor xenograft study 
Animal studies were approved and carried out 
in accordance with Institutional Animal Care and Use 
Committee of Model Animal Research Center, 
Nanjing University. 5×106 of T24, 5637 and 
lncRNA-LET stable over-expression cells (vector 
control and pLET) in 0.1 ml 50% Matrigel were 
injected subcutaneously into the right flank of 
4~6-week-old male nude mice. 10 days post 
inoculation, tumor-bearing mice were randomized to 
saline or GEM groups. GEM (50 mg/kg body weight) 
was given on day 1, 4, 8 and 11 via intraperitoneal 
injection. Tumor diameters were measured with 
calipers every 3 days and tumor volumes were 
calculated by the formula: tumor volume = π× length 
× width2/6. The tumors were harvested 24 h after the 
last treatment and snap frozen or fixed in 10% 
formalin, followed by embedding in paraffin. 
Xenografts were rinsed in PBS and mechanically 
minced with sterile blades in RPMI1640/5% FBS with 
antibiotics/antimycotics and digested with 0.5% 
trypsin for 5 to 10 minutes at 37°C. The dissociated 
cells were strained through strainer (BD) and cultured 
as primary cells. Cell viability was verified by trypan 
blue exclusion before FACS analysis, sphere assays or 
immunoblotting. 
To investigate combined TGFβ signaling 
inhibition and gemcitabine treatment, we treated mice 
with type I TGFβ receptor kinase inhibitor LY2157299 
(100 mg/kg body weight, Selleck) twice a day via 
orogastric gavage and GEM (50 mg/kg body weight) 
on day 1, 4, 8 and 11 via intraperitoneal injection. 
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Limiting dilution analysis of tumor 
subpopulations 
shCTL and shLET cells were serially diluted to 
the designated cell number, followed by the 
subcutaneous injection into nude mice. The number of 
tumors formed from each injection was scored. The 
frequency of CSCs had been calculated using ELDA 
software 
(http://bioinf.wehi.edu.au/software/elda/index.ht
ml) provided by the Walter and Eliza Hall Institute. 
Immunohistochemistry (IHC) 
5 µm-thick paraffin-embedded sections were 
used for IHC staining. Primary antibodies against 
CK5 (Covance, PRB-160P) and CK14 (Covance, 
PRB-155P) were incubated overnight at 4°C. After 
washing, biotinylated secondary antibody (Maxin, 
KIT-9707) was applied, followed by the procedures 
described previously (17).  
Statistics 
Data are presented as mean±standard deviation 
(SD) from three independent experiments unless 
specially stated. Mann Whitney test, Unpaired t test or 
Wilcoxon signed rank test was used to compare the 
differences of the level between cancer tissues and 
corresponding normal tissues. Other differences 
between groups were analyzed using Student’s t test 
or One-way ANOVA followed by Newman-Keuls 
multiple comparison test. Pearson correlation test was 
used for analyzing the correlation between two 
continuous factors. The log-rank (Mantel-Cox) t-test 
was used for survival analysis. P value less than 0.05 
was considered statistically significant.  
Results 
GEM treatment enriches UBC stem-like cells 
To mimic the process of tumor recurrence in 
GEM-treated patients, we first inoculated human 
UBC cell lines T24 or 5637 into nude mice 
subcutaneously and then 50 mg/kg of GEM were 
administered to the mice on days 1, 4, 8 and 11, 
followed by a two-week recovery period. The second 
round treatment started on day 29 for mice with T24 
and 5637 xenografts, and the third round treatment 
started on day 57 for mice carrying 5637 xenografts. 
As shown in Fig. 1A and Fig. S1A, overall the tumors 
derived from either of these cell lines grow much 
slower in the GEM-treated mice than those in the 
vehicle group. During the first two weeks, GEM 
almost completely inhibited the growth of tumors 
derived from either of these cell lines. During the 
two-week recovery period, tumors grew much faster 
in control group, although the tumor growth rate was 
still lower in the GEM group. However, GEM failed to 
inhibit the growth of T24 and 5673 xenografts in the 
second and the third round of treatment, respectively.  
To explore the possibility that some of the tumor 
cells become resistance to GEM treatment due to a 
subpopulation of CSCs, we sacrificed the mice and 
collected tumor samples at the end of the 2nd round 
(T24 xenografts) and the 3rd round (5637 xenografts) 
of treatments for further analyses. Firstly, we isolated 
cancer cells from xenografts and performed sphere 
assays. As shown in Fig. 1B and Fig. S1B, compared to 
that in the vehicle group, cells in GEM-treated group 
increased the number of spheres derived from T24 
and 5637 xenografts by 2.3 and 2.2 folds, respectively. 
Consistently, IHC analyses showed that two UBC 
stemness markers CK5 and CK14 (18) were highly 
expressed in the GEM-treated xenografts (Fig. 1C and 
Fig. S1C). Furthermore, Western blotting showed that 
another four CSC markers (ALDH1A1, CD44, KLF4 
and HMGA2) (19-24) elevated dramatically in the 
GEM-treated samples (Fig. 1D and Fig. S1D). Finally, 
we treated T24 and 5637 cells in vitro with GEM at IC50 
values for T24 (3.8 μM) and 5637 (6.4 μM) cells, 
respectively, followed by the removal of GEM for 
cancer cell recovery (Fig. S2A and S2B). Compared 
with the vehicle, GEM treatment significantly 
increased the ALDHhigh population from 7.9% to 
12.6% for T24 cells, and from 9.7% to 19.0% for 5637 
cells (Fig. S2C). GEM-treatment also increased the 
CD44+ subpopulation, another CSC marker for UBC 
cells (Fig. S2D) and the levels of different CSC 
markers (Fig. S2E). Taken together, these data suggest 
that GEM treatment can enrich the CSC 
subpopulation in UBC.  
Downregulation of lncRNA-LET negatively 
correlates with cancer stemness 
To determine if lncRNAs play any roles in CSC 
enrichment resulted from GEM treatment, we carried 
out cancer-related lncRNA PCR array. GEM treatment 
upregulated 14 and 6 lncRNAs in T24 and 5637 
xenografts, respectively; meanwhile 5 and 14 
lncRNAs were downregulated by GEM treatment, 
respectively. Among them, lncRNA-LET was the only 
lncRNA that was downregulated more than 2 folds in 
GEM-treated xenografts derived from both T24 and 
5637 cells (Table S2). The array results were further 
validated in these cell lines treated with or without 
GEM (Fig. 1E). LncRNA-LET was first found to be 
downregulated in hepatocellular carcinomas (25). 
However, its exact function in chemoresistance is 
unclear. Therefore, we decided to focus on this 
lncRNA for further study.  
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Figure 1. Cancer stemness markers in cells treated with chemotherapeutic agents in vivo, and downregulation of lncRNA-LET enhances 
CSC-like properties. (A) In vivo GEM chemotherapy simulates clinical regimen with multiple GEM treatment cycles (dashed boxes) and gap periods. Tumor sizes 
of T24 xenografts were measured for GEM treatment and vehicle control group (n = 6 per group). (B) Sphere formation assay of primary cells derived from T24 
xenografts of control group (Veh) and GEM (n=3 per group). (C) Representative H&E and IHC data showing the expression levels of CSC markers (CK5 and CK14) 
in T24 xenografts of control and GEM groups (n = 6 per group). (D) Western blotting of CSC markers (ALDH1A1, CD44, KLF4, and HMGA2) in T24 xenografts of 
control and GEM groups. (E) The levels of lncRNA-LET in T24 and 5637 cells treated with GEM or vehicle. (F) Knockdown efficiency of lncRNA-LET in T24 cells and 
forced expression of lncRNA-LET in J82 cells. (G-H) ALDHhigh population (G) and CSC markers (H) were determined by flow cytometer and Western blotting in T24 
with knockdown and J82 cells with overexpression of lncRNA-LET (n=3 per group). (I) Knockdown efficiency of lncRNA-LET in T24 cells infected with shRNA 
targeting lncRNA-LET virus (shLET), compared to control (shCTL). (J) Tumor volume of shCTL and shLET T24 cells with limiting dilution. Each dot represents an 
individual mouse (n=6 per group). Data are shown as mean ± SD and represent three independent experiments with similar results. * P < 0.05; ** P < 0.01, *** P < 
0.001 (Student’s unpaired two-tailed t-test). (K) CSC frequency was calculated using extreme limiting dilution analysis (ELDA). There was a significant difference in 
CSC frequency between two groups, with a P value of 0.025. 
 
Next, we examined the expression of 
lncRNA-LET in several UBC cell lines. 5637 cells 
express the highest levels of lncRNA-LET, followed 
by T24 cells and the least in J82 cells (Fig. S1E). To 
determine the effect of lncRNA-LET on cancer 
stemness in UBC cells, lncRNA-LET was knocked 
down by two siRNAs, siLET-#1 and siLET-#2, in T24 
and 5637 cells and overexpressed in J82 cells (Fig. 1F 
and Fig. S1F). The ALDHhigh populations and the 
levels of cancer stemness markers were assessed. As 
shown in Fig. 1G and Fig. S1G, depletion of 
lncRNA-LET increase ALDHhigh populations in T24 
and 5637 cells. On the other hand, overexpression of 
lncRNA-LET in J82 cells reduced the ALDHhigh 
population by about 50% (Fig. 1G). Western blotting 
further confirmed the inhibitory effects of 
lncRNA-LET on UBC stemness, evidenced by the 
levels of CSC markers (Fig. 1H and Fig. S1H).  
To further confirm the effects of lncRNA-LET on 
UBC stemness in vivo, we then established 
lncRNA-LET stable knockdown cells (shLET; Fig. 1I), 
and conducted the limiting dilution assay to 
rigorously test the cells’ tumor-initiating capacity. We 
found that depletion of lncRNA-LET significantly 
increased both cancer incidence and tumor volumes 
(Fig. 1J and K). To test whether forced expression of 
lncRNA-LET can reverse tumor recurrence in vivo, we 
stably overexpressed lncRNA-LET in T24 cells (Fig. 
2A), and as expected that overexpression of 
lncRNA-LET reduced the levels of the stemness 
markers (Fig. 2B). Then we inoculated the cells with 
lncRNA-LET overexpression into nude mice, 
 Theranostics 2017, Vol. 7, Issue 12 
 
 
http://www.thno.org 
3058 
followed by GEM treatment. As shown in Fig. 2C-D, 
forced expression of lncRNA-LET increased tumor 
latency with GEM treatment. IHC data showed that 
CK5 and CK14 were highly induced by GEM 
treatment in control but not the lncRNA-LET group 
(Fig. 2E). These data collectively demonstrate that 
lncRNA-LET is essential and sufficient for 
maintenance of UBC stemness, whereas forced 
overexpression of lncRNA-LET could partially 
reverse chemoresistance in UBC.  
LncRNA-LET is suppressed by TGFβ1 
signaling in chemoresistant cells 
Given the facts that inflammation was proposed 
to be involved in the development of cancer stemness 
and GEM treatment might induce inflammation (9), 
we decided to determine if downregualtion of 
lncRNA-LET by GEM treatment is due to the 
activation of the inflammatory pathway. We 
examined a few well-established pro-inflammatory 
cytokines in T24 xenografts treated with or without 
GEM. Among these factors, TGFβ1 is significantly 
increased when the cells were treated with GEM 
accompanied with a couple of factors directly 
involved in the TGFβ signaling pathway (Fig. S3A). 
This observation was also substantiated by Western 
blotting, showing phosphorylated SMAD2 
(p-SMAD2) in T24 xenografts by GEM treatment (Fig. 
3A). In addition, the levels of lncRNA-LET were 
downregulated by TGFβ1 in both cell lines, and this 
effect was likely through TGFβRI because the 
TGFβ1-downregulated lncRNA-LET was successfully 
rescued by treating cells with either TGFβRI inhibitor 
SB-431542 (Fig. 3B and Fig. S3B) or SMAD4 siRNAs 
(Fig. 3C and Fig. S3C). Furthermore, TGFβ1 enhanced 
cancer stemness, evidenced by its effects on the 
number of spheres (Fig. S3D-E) and the ALDHHigh 
subpopulation (Fig. S3F). Overall, both TGFβRI and 
SMAD4 are important for TGFβ1-induced cancer 
stemness and the level of lncRNA-LET.  
 
 
 
Figure 2. The role of lncRNA-LET in GEM-induced cancer stemness. (A) qRT-PCR showed stable overexpression of lncRNA-LET in T24 cells (pLET). (B) 
CSC markers were determined by Western blotting in T24 cells overexpressed lncRNA-LET and control vector. (C-E) Tumor size change (C), the levels of 
lncRNA-LET (D) and representative IHC (E) of xenografts from control (Vec) and overexpression (pLET) cells after GEM or vehicle treatment (Vec+Veh group n=5, 
other group n=6). Dashed boxes indicate the time frame of each GEM chemotherapy cycle. Data are shown as mean ± SD and represent at least two independent 
experiments with similar results. * P < 0.05, ** P < 0.01, *** P < 0.001 (One-way ANOVA followed by Newman-Keuls multiple comparison test). 
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Figure 3. TGFβ1 represses lncRNA-LET expression in UBC cells. (A) Western blotting showing the levels of p-SMAD2 and total SMAD2 in xenografts 
treated with or without GEM. (B-C) mRNA levels of lncRNA-LET were measured by qRT-PCR in T24 and 5637 cells treated with or without TGFβ1 or TGFβR1 
inhibitor, SB-431542, as well as transfected with control (siNC) or 2 different RNAi of SMAD4 (siSMAD4#1, siSMAD4#2), followed by vehicle or TGFβ1 treatment. 
(D) Conserved SMAD4 binding element (SBE) in the promoter of human and Rhesus Monkey lncRNA-LET. (E) Relative luciferase activity in T24 cells transfected 
with plasmids of wild type (pGL3-LET-WT) and SBE deleted (pGL3-LET-ΔSBE) lncRNA-LET promoter, respectively, followed by treatment with vehicle or TGFβ1. 
(F-G) Sphere numbers (F) and expression of CSC markers (G) in T24 and 5637 cells treated with TGFβ1 alone or TGFβ1 and forced expression of lncRNA-LET. 
Data are shown as mean ± SD and represent at least two independent experiments with similar results. * P < 0.05, ** P < 0.01, *** P < 0.001 (Student’s unpaired 
two-tailed t-test). 
 
Additionally, results from bioinformatic analysis 
identified a conserved SMAD binding element (SBE) 
in the promoter region of lncRNA-LET (Fig. 3D). The 
wild-type or ∆SBE-mutant lncRNA-LET promoter 
sequence was cloned into pGL3-basic plasmid and 
luciferase activities were measured in cells treated 
with or without TGFβ1. Fig. 3E shows that TGFβ1 
repressed the promoter activity of wild-type but not 
the mutant reporter, suggesting that lncRNA-LET is a 
downstream target of the canonical TGFβ signaling 
pathway. To further validate the essentiality of 
lncRNA-LET downregulation in TGFβ-induced 
cancer stemness, we forcedly expressed lncRNA-LET 
in T24 and 5637 cells. Overexpression of lncRNA-LET 
reversed TGFβ1-induced cancer stemness, with 
increase of sphere number (Fig. 3F) and the 
expression levels of CSC markers (Fig. 3G). These data 
collectively demonstrate that lncRNA-LET negatively 
regulates TGFβ1-induced cancer stemness.  
NF90 is essential in GEM-induced 
lncRNA-LET-mediated UBC stemness 
Since lncRNA-LET has been implicated in the 
regulation of NF90 protein stability in hepatocellular 
carcinoma (25), we decided to examine if NF90 is 
regulated by lncRNA-LET in UBC. As shown in Fig. 
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4A and Fig. S4A, knockdown of lncRNA-LET 
increased NF90 protein level in both T24 and 5637 
cells; whereas forced expression of lncRNA-LET in J82 
cells reduced the level of NF90. To test whether 
lncRNA-mediated NF90 downregulation is through 
enhancing protein degradation, we treated cells with 
cycloheximide (CHX) and evaluated NF90 levels at 
different time points. The half-life of NF90 was about 
12 h in the control, which was reduced to about 3 h in 
the cells with lncRNA-LET overexpression (Fig. 4B), 
suggesting that lncRNA-LET-mediated NF90 
downregulation was through enhancing protein 
degradation. In addition, NF90 protein degradation 
by lncRNA-LET was significantly inhibited in the 
presence of MG-132, an inhibitor against 26S 
proteasome, indicating the involvement of the 26S 
proteasome system (Fig. S4B). Next, we tested 
whether NF90 is required for lncRNA-LET-mediated 
cancer cell stemness. Consistent with the 
aforementioned experiments, lncRNA-LET depletion 
increased ALDHhigh populations in both T24 and 5637 
cells. However, simultaneous knockdown of NF90 
and lncRNA-LET significantly reduced ALDHhigh 
population, compared to knockdown of lncRNA-LET 
alone (Fig. 4C and Fig. S4C). These findings were 
further verified by Western blotting (Fig. 4D and Fig. 
S4D). Given the fact that GEM could increase NF90 at 
protein level in GEM-resistant cells (Fig. 4E and Fig. 
S4E) and knockdown of NF90 reduces GEM-induced 
ALDHhigh population and CSC markers (Fig. 4F-G and 
Fig. S4F), we conclude that NF90 is essential for 
GEM-induced lncRNA-LET-mediated UBC stemness. 
 
 
Figure 4. The stabilized NF90 by the reduced lncRNA-LET is required for cancer cell stemness. (A) Western blotting showing NF90 protein level in 
T24 with depletion of lncRNA-LET and J82 cells with overexpression of lncRNA-LET. (B) Protein level of NF90 in J82 cells over-expressed lncRNA-LET, followed by 
50 μg/ml cycloheximide (CHX) treatment for the indicated time points. (C-D) ALDHhigh population (C) and expression of CSC markers (D) were determined by 
flow cytometer and Western blotting in control (siNC), lncRNA-LET knockdown (siLET#2), and simultaneous knockdown lncRNA-LET and NF90 (siLET#2 + 
siNF90#1 or siLET#2 + siNF90 #2) of T24 cells (n=3 per group). (E) Protein level of NF90 was determined by Western blotting in untreated and GEM resistant T24 
cells. (F) The ALDHhigh population was determined by flow cytometer in control (siNC) and NF90 knockdown (siNF90 #1 and #2) T24 cells treated with or without 
GEM. (G) Western blotting showing the levels of CSC markers in control (siNC) and NF90 knockdown (siNF90 #1 and #2) T24 cells, followed by the treatment with 
or without GEM. Data are shown as mean ± SD and represent at least two independent experiments with similar results. * P < 0.05, ** P < 0.01, *** P < 0.001 
(Student’s unpaired two-tailed t-test). 
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NF90 negatively regulates miR-145 biogenesis 
As a RNA binding protein, NF90 plays an 
important role in mRNA stability and miRNA 
biogenesis (26). We first tested the effect of NF90 on its 
two known targets VEGF and HIF1α in 5637 cells and 
found that lncRNA-LET depletion upregulated NF90 
and VEGF at protein levels, but not HIF1α, probably 
due to different cell type (Fig. S5A). Since the role of 
VEGF in UBC cell stemness is not well-established 
and it has been reported that NF90 could be involved 
in miRNA biogenesis, we conducted microarray assay 
to identify miRNAs potentially regulated by NF90 
(GSE 82024) and found that NF90 knockdown 
resulted in upregulation of 25 miRNAs (≧ 2 folds) 
and downregulation of 9 miRNAs (≦ 0.5 fold) (Fig. 
5A). Among them, miR-145 was the most highly 
upregulated miRNAs with 22.5-fold induction. Of 
note, although miR-143 and miR-145 locate in the 
same region on the chromosome, the levels of miR-143 
was not affected significantly under the same 
condition.  
Next, we validated the effect of NF90 on miR-145 
in T24 and 5673 cells with miR-143 as a control. Fig. 5B 
showed that when NF90 was knocked down by 
siNF90 #1, miR-145 was upregulated by 22.6 and 14.7 
folds in T24 and 5637 cells, respectively. Another 
siRNA targeting different region of NF90 (siNF90 #2) 
was also used and confirmed the induction of 
miR-145 when NF90 was depleted (Fig. S5B, left 
panel). However, NF90 knockdown had no effects on 
miR-143 (Fig. S5B, middle and right panels). 
Consistent with the fact that NF90 is a lncRNA-LET 
target and NF90 knockdown upregulated miR-145, 
inhibition of lncRNA-LET resulted in downregulation 
of miR-145 in both cell lines (Fig. 5C). Again, knocking 
down lncRNA-LET had undetectable effect on 
miR-143 (Fig. 5D). Consistently, lncRNA-LET 
overexpression was capable of upregulating miR-145 
without affecting miR-143 (Fig. S5C). To test whether 
NF90 regulates miR-145 through direct interaction, 
we conducted RIP assay. As shown in Fig. 5E, NF90 
interacted specifically with pri-miR-145, but not 
pri-miR-143. To demonstrate that NF90 interacts with 
pri-miR-145 through the conserved NF90 binding 
sequence (27), we synthesized both wild-type and 
mutant miR-145 with the change of 5’-CTGTT-3’ to 
5’-CTGCC-3’ and estimated the effect of NF90 on 
these pri-miRNAs (Fig. 5F). Fig. 5G showed that 
overexpressed NF90 could downregulate the 
wild-type but not the mutant miR-145 (top panel), 
although the levels of overexpressed NF90 were 
comparable under different transfection conditions 
(bottom panel). These data collectively indicate that a 
lncRNA-LET/NF90/miR-145 axis exists in UBC cells. 
 
 
Figure 5. NF90 regulates miR-145 biogenesis. (A) Cluster map of microarray showed the altered miRNAs ≥ 2 folds in NF90 knockdown cells, compared with 
control group (siNC). (B) mRNA level of miR-145 was measured by qRT-PCR in control (siNC) and NF90 knockdown (siNF90) T24 and 5637 cells. (C) qRT-PCR 
showing the level of miR-145 in control (siNC) and lncRNA-LET knockdown (siLET-#1 and siLET-#2) T24 cells. (D) The levels of miR-145 and miR-143 in control 
(shCTL) and lncRNA-LET stable knockdown (shLET) T24 cells. (E) RIP combined with qRT-PCR assays of NF90 binding to pri-miR-143 or pri-miR-145 in control 
(shCTL) or lncRNA-LET knockdown (shLET) T24 cells. Relative enrichment of pri-miRNAs in anti-NF90 group, compared with IgG group. The control GAPDH 
mRNA level was used for normalization. (F) Schematic illustration of wild-type (WT) and mutant (Mut) miR-145 with consensus binding motif of NF90. (G) qRT-PCR 
analysis of exogenous miR-145 levels in T24 cells, transfected with wild-type or mutant NF90 binding site pri-miR-145 vector. Expression of FLAG in Western blotting 
was used to represent the NF90 transfection efficiency. Data are shown as mean ± SD and represent at least two independent experiments with similar results. * P 
< 0.05, ** P < 0.01, *** P < 0.001 (Student’s unpaired two-tailed t-test). 
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miR-145 suppresses markers of cancer 
stemness 
To determine if miR-145 plays any role in cancer 
stemness, we transfected miR-145 mimic into UBC 
cells and monitored its effect on stemness markers. 
Fig. S5D shows that miR-145 repressed GEM-induced 
ALDHhigh population. Western blotting data further 
confirmed the effect of miR-145 on CSC population 
evidenced by the cancer stemness markers in T24 cells 
(Fig. S5E). Bioinformatic analyses found that both 
KLF4 and HMGA2 contain a potential miR-145 
binding site in their 3’-UTRs (Fig. S5F). We then 
co-transfected T24 cells with miR-145 and reporters 
driven by either wild-type or mutant 3’-UTRs of the 
KLF4 or the HMGA2 and studied the effects of 
miR-145 on reporter activity. Fig. S5G shows that 
miR-145 inhibited reporter activities controlled by 
wild-type, but not mutant 3’-UTRs of either gene, 
suggesting that miR-145 is involved in the 
downregulation of these stemness markers. 
Consistently, ectopic expression of both KLF4 and 
HMGA2 were able to rescue the inhibitory effects of 
miR-145 against cancer stemness (Fig. S5H-I). 
Inhibition of TGFβ1 signaling pathway 
suppressed GEM-induced UBC stemness 
Next, we examined whether TGFβ signaling 
pathway is involved in GEM-induced cancer 
stemness. Using the protocol that UBC cells were 
transiently treated with GEM followed by removal of 
GEM for cancer cell recovery (Fig. S2A and S2B), we 
observed that GEM treatment increased ALDHHigh 
subpopulation in T24 cells. However, depletion of 
SMAD4 by RNA interfering significantly reversed the 
induction of CSC population (Fig. S6A), supported by 
consistent changes of CSC markers expression levels 
(ALDH1A1 and CD44; Fig. S6B). To further validate 
whether lncRNA-LET/NF90/miR-145 axis are 
regulated by TGFβ1 pathway in GEM resistant UBC 
cells, we performed qRT-PCR and found that GEM 
treatment-repressed lncRNA-LET and miR-145 were 
significantly increased when SMAD4 was depleted 
(Fig. S6C and S6D). Western blotting data also 
confirmed that GEM treatment stabilized NF90 
protein, which was abrogated once SMAD4 was 
knocked down (Fig. S6B). Overall, in vitro data 
supported the notion that alteration of 
lncRNA-LET/NF90/miR-145 axis by TGFβ1 signaling 
accounts for GEM-mediated regulation of UBC 
stemness.  
Inhibition of TGFβ1 signaling pathway 
sensitized GEM-resistant xenograft to 
chemotherapy 
Given that activation of TGFβ1 signaling 
pathway in recurrent UBC xenografts under GEM 
treatment, which is essential for cancer cell stemness, 
we hypothesize that targeting TGFβ1 pathway may 
reduce CSC population and enhance efficacy of 
chemotherapy. To examine this hypothesis, we s.c. 
injected chemoresistant T24 cells, which were 
primarily cultured from recurrent xenografts under 
GEM treatment. Once we followed previous regimen, 
GEM showed slight anticancer effects; while 
LY2157299, a specific inhibitor to type I TGFβ receptor 
kinase, did not show remarkable reduction. Notably, 
combined treatment with LY21577299 and GEM 
significantly and strikingly repressed tumorigenicity 
in vivo (Fig. 6A and B). By primarily culturing cancer 
cells from four different T24 xenograft groups, we 
found that, compared to untreatment group, 
suppressing TGFβ1 pathway significantly reduced 
CSC population, though GEM alone did not further 
enrich CSC subpopulation in GEM-resistant T24 cells 
derived from previous GEM treatment (Fig. 6C). 
Western blotting data confirmed the successful 
inhibition of TGFβ1 pathway (Fig. 6D). Taken 
together, targeting TGFβ1 pathway may be a 
promising approach to suppress GEM 
treatment-induced cancer stemness and sensitize UBC 
cells to chemotherapy. 
Clinical relevance of 
lncRNA-LET/NF90/miR-145 axis in UBC 
specimens 
To determine the significance of the 
TGFβ1/lncRNA-LET/NF90/miR-145 regulatory axis 
in clinical UBC specimens, we analyzed their 
expression levels in 60 UBC samples and 48 adjacent 
normal tissues. Compared with those in the normal 
tissues, the levels of NF90 and TGFβ1 in these human 
UBC samples were significantly increased about 5.0 
(Fig. 7A-B) and 1.5 folds (Fig. 7B), respectively. On the 
other hand, the levels of lncRNA-LET and miR-145 in 
tumors were significantly reduced by about 52% and 
92%, respectively (Fig. 7A). The expression level of 
lncRNA-LET is significantly associated with tumor 
stage, microvascular invasion, lymph node metastasis 
and recurrence (Table S3). More importantly, the level 
of lncRNA-LET in tumor tissues was negatively 
correlated with TGFβ1 (r = -0.6083; P < 0.0001) and 
NF90 (r = -0.4814; P = 0.0017), but positively 
correlated with miR-145 (r = 0.4967; P < 0.0001; Fig. 
7C). To examine the prognostic significance of TGFβ1, 
lncRNA-LET, and miR-145 expression levels, we 
performed Kaplan-Meier survival analysis of UBC 
patients. UBC patients which displayed lower 
expression levels of lncRNA-LET and miR-145 had a 
reduced survival rate, whereas TGFβ1 expression 
level did not show significant difference in clinical 
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outcome. Moreover, UBC patients with a profile of 
TGFβ1low/lncRNA-LEThigh/miR-145high showed a 
better survival rate compared with patients with other 
expression profiles, such as TGFβhigh 
/lncRNA-LETlow/miR-145low (Fig. 7D). Overall, these 
data suggest that TGFβ1high/lncRNA-LETlow/ 
miR-145low signature could be served as a predictor of 
clinical outcome in UBC patients. 
Discussion 
Tumor chemoresistance and subsequent relapse 
are common in cancers, which raises a key issue for 
clinicians. Accumulating evidence supports the 
notion that a small population of CSCs inside the 
heterogeneous tumor bulk could be accountable for 
tumor recurrence (8, 28). The CSCs have intrinsic 
chemoresistant properties and can be selectively 
enriched during chemotherapy. In this study, we 
found that UBC stemness is enhanced during 
chemotherapy with GEM in vivo, evidenced by the 
increased levels of CSC markers, such as CK14, CK5 
and CD44. This is consistent with the observation that 
cytotoxic chemotherapy induced CK14+ cancer cell 
proliferation despite reducing tumor size at initial 
chemotherapy cycle (29). Based on the data from both 
in vitro and in vivo experiments, we propose that 
TGFβ1 is upregulated by GEM treatment, and the 
TGFβ1-mediated dysregulation of the 
lncRNA-LET/NF90/miR-145 axis promotes cancer 
cell stemness in residual tumors and subsequently 
results in chemoresistance (Fig. 7E). 
LncRNAs have been found to be frequently 
dysregulated in cancers and implicated in cancer 
stemness and chemoresistance (30, 31). LncRNA-LET 
has been reported to be underexpressed in cancers of 
digestive system and associated with cancer 
metastasis (25, 32, 33). We found that lncRNA-LET 
was also down-regulated in chemoresistant human 
UBC xenografts. The downregulation of lncRNA-LET 
was accompanied by increased NF90 protein stability, 
reduced biogenesis of miR-145, as well as elevated 
levels of stemness markers. These data indicate that 
lncRNA-LET plays a central role in the regulation of 
UBC stemness because forced expression of 
lncRNA-LET reduces UBC stemness markers and 
delays tumor relapse. 
 
 
Figure 6. Inhibition of TGFβ1 signaling pathway enhances chemosensitivity to GEM treatment in T24 UBC xenografts. (A) Tumor size change of 
xenografts from chemoresistant T24 cells treated with vehicle, LY2157299, GEM or both LY2157299 and GEM (n=6 per group). (B) Tumor volumes calculated on 
day 30 (n=6 per group). (C) ALDEFLUOR assay. The primary cells derived from xenografts were harvested on day 30, and analyzed for ALDH activity. (D) Western 
blotting of pSMAD2 and total SMAD2 in xenografts of the four groups. Data are shown as mean ± SD. ** P < 0.01 (Student’s unpaired two-tailed t-test). 
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Figure 7. Clinical relevance of lncRNA-LET/NF90/miR-145 axis in UBC specimens. (A). The levels of lncRNA-LET, TGFβ1, miR-145, and that of NF90 in 
human UBC (Tumor) and the adjacent normal tissues (Normal). Mann Whitney test, Unpaired t test or Wilcoxon signed rank test was used for analysis of statistical 
significance. (B) Western blotting showing NF90 expression in paired UBC (T) and adjacent normal tissues (N). (C) The correlations among lncRNA-LET, TGFβ1, 
miR-145 and NF90 were determined by Pearson correlation analysis. ΔCT values of qRT-PCR were used as the levels of lncRNA-LET, TGFβ1 and miR-145 
transcripts. NF90 protein bands on Western blotting were semi-quantified by Image J. (D) Kaplan-Meier survival analysis of overall survival of 60 UBC patients with 
expression profile of TGFβ1high vs TGFβ1low, lncRNA-LET high vs lncRNA-LETlow, miR-145 high vs miR-145low. Subgroup analysis of UBC patients according to the 
expression profile of TGFβ1high/lncRNA-LETlow/miR-145low signature versus the other combinations. Median value was chosen as cut-off point. The log-rank 
(Mantel-Cox) test was used to calculate P-values. P < 0.05 was considered statistically significant. (E) Schematic illustration of enhancement of cancer stem-like cell 
properties in GEM resistant UBC cells by the dysregulation of lncRNA-LET/NF90/miR-145 axis via TGFβ1. 
 
Maintenance of cancer stemness can also be 
regulated by extracellular cue. We found that in 
GEM-treated UBC xenografts TGFβ1 was upregulated 
and functional. This is consistent with the recent 
report showing that TGFβ signaling was strongly 
activated after paclitaxel treatment in triple-negative 
breast cancer tissues (34). The induction of TGFβ1 
could be the results of autocrine or paracrine. We 
have reported that cancer-associated fibroblasts in 
tumor microenvironment is capable of enhancing the 
expression of TGFβ1 than cancer cells (35). In 
addition, TGFβ1 could also be derived from other cell 
types, including immune cells which are often 
recruited to tumor region during therapy (36, 37). 
Nevertheless, down-regulation of lncRNA-LET by 
overactivation of TGFβ/SMAD signaling pathway in 
UBC cells suggests cytokines such as TGFβ1 play 
important role in the regulation of UBC stemness.  
We demonstrated that in different UBC cell lines 
lncRNA-LET could increase NF90 degradation 
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through the ubiquitin-proteasome pathway, similar to 
that in hepatoma cell lines (25). NF90 is a 
double-stranded RNA binding protein involved in 
stabilization, turnover and translational control of 
different target mRNAs, including interleukin 2 
(IL-2), hypoxia-inducible factor 1 alpha (HIF-1α) and 
vascular endothelial growth factor (VEGF) (25, 38-40). 
We found that VEGF, but not HIF-1α, was elevated in 
UBC cells with knockdown of lncRNA-LET. This 
suggests that in UBC cells the lncRNA-LET/NF90 axis 
regulating VEGF and HIF1 differently. In addition to 
regulating the expression of different genes 
post-transcriptionally, NF90 also takes part in miRNA 
biogenesis. As a competitor for the association of the 
microprocessor complex with pri-miRNAs, NF90 
usually inhibits miRNA production (27, 41, 42). We 
found that lncRNA-LET depletion resulted in 
elevated level of NF90 which in turn blocks miR-145 
biogenesis by competitively binding to pri-miR-145 
specifically. Of note, both miR-143 and miR-145 locate 
on chromosome 5q33 with approximately 1.3 kb away 
from each other. An 11 kb transcript serves as the 
precursor of both miRNAs, albeit miR-145 can be 
generated from another 1.9 kb transcript precursor 
(43). It has been proposed previously that during 
bladder CSCs enrichment the expression of miR-145 
could be regulated by an undefined mechanism (44, 
45). Here we demonstrated that miR-145 biogenesis 
can be regulated by lncRNA-LET/NF90 axis. 
Although it is known that miR-145 negatively 
regulates human embryonic stem cells and CSCs, it is 
unclear whether it regulates the stemness markers 
indirectly or directly (45-48). We demonstrated in this 
report that in UBC cells KLF4 and HMGA2, two 
miR-145 targets, are responsible for miR-145 mediated 
inhibition of UBC cell stemness.  
In the current study, we also examined whether 
TGFβ signaling pathway could be a promising 
therapeutic target to enhance chemosensitivity of 
UBC cells to GEM in vivo. LY2157299, also known as 
galunisertib, is a selective ATP-mimetic inhibitor of 
TGF-βRI serine/threonine kinase. It displayed 
antitumor activity, as well as acceptable tolerability 
and safety profile in cancer patients with advanced 
tumors, such as glioma (49-51). In the in vivo study 
herein, combined treatment of LY2157299 with GEM 
significantly reduced CSC subpopulation and 
tumorigenecity compared with either drug alone. This 
intriguing data support the notion that overactivation 
of TGFβ signaling pathway during tumor relapse can 
serve as a promising therapeutic target for UBC 
patients under chemotherapy.  
In conclusion, our data demonstrated that GEM, 
which is commonly used for the treatment fo UBC 
patients, can induce TGFβ1 in recurrent tumors. The 
elevated TGFβ1 induces a regulatory axis of 
lncRNA-LET/NF90/miR-145 in UBC cells to increase 
CSC populations and promote chemoresistance. The 
notion that TGFβ1high/lncRNA-LETlow/miR-145low 
signature in clinical samples were correlated with 
poor prognosis reinforces the importance of this 
regulatory axis for UBC patients. Interestingly, forced 
expression of lncRNA-LET maintained the sensitivity 
of UBC cells to GEM and delaying tumor relapse, 
suggesting that either targeting TGFβ signaling 
pathway, restoration of lncRNA-LET expression or 
reintroduction of its downstream target miRNA could 
be an attractive anti-tumor approach for integrated 
cancer therapy (49, 52, 53). 
Statement of translational relevance 
Gemcitabine is commonly used in combinatory 
chemotherapy for muscle invasive bladder cancer 
patients in the neoadjuvant, adjuvant and palliative 
setting. However, the duration of response in various 
combinations and survival results is limited in the 
advanced or metastatic bladder cancers. Hence, it is 
needed for biomarkers of prognosis and drug 
response, as well as potential drug targets. To address 
this question, we identified that lncRNA-LET is 
downregulated in gemcitabine resistant bladder 
cancers, which is directly and negatively regulated 
pro-inflammatory cytokine TGFβ1. Importantly, the 
forced expression of lncRNA-LET delays bladder 
cancer recurrence under gemcitabine treatment. We 
also identified that lncRNA-LET/NF90/miR-145 axis 
in recurrent bladder cancer samples will provide 
better understanding of maintenance of cancer cell 
stemness. Moreover, the combined changes in 
TGFβ1/lncRNA-LET/miR-145 provide novel 
molecular prognostic markers in bladder cancer 
outcome. Abrogation of TGFβ1 pathway by 
LY2157299 sensitized bladder cancer cells to 
gemcitabine in vivo. 
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